Tenaya Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Tenaya Therapeutics, Inc. filed a Current Report on Form 8-K dated November 17, 2021, with the report signed and filed on November 22, 2021. The filing concerns changes to the company’s board of directors and does not report results for a financial reporting period.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes
- JeenJoo Kang, Ph.D., resigned as a director on November 17, 2021. The resignation was voluntary and was not due to any disagreement with the company or its board.
- On November 19, 2021, the board appointed June Lee, M.D., as a Class III director, with a term expiring at the 2024 annual meeting of stockholders.
- The filing states that there were no arrangements or understandings regarding Dr. Lee’s selection and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Compensation, Outlook, and Risks
- Dr. Lee will receive the standard non-employee director compensation, including an annual cash retainer of $35,000.
- Dr. Lee received a stock option with an approximate grant-date fair value of $320,000. The option vests monthly over 36 months, subject to continued service.
- The option will vest in full upon a change in control if Dr. Lee remains a non-employee director through that date.
- Dr. Lee also entered into the company’s standard indemnification agreement.
- The filing provides no financial guidance, business outlook, contingencies, or unusual operating items.
Investor Verification Items
- Verify the effective dates: the earliest reported event was November 17, the board appointment occurred November 19, and the related press release was dated November 22, 2021.
- Review the company’s director compensation policy and the terms of Dr. Lee’s stock option, including vesting and change-in-control provisions.
- Assess any resulting changes in board composition, committee assignments, governance, or director independence in subsequent filings.
- Consult subsequent periodic filings for financial performance, liquidity, capital requirements, and broader corporate developments, none of which are presented here.